BETULONIC ACID DIPEPTIDE -
A NON-NUCLEOSIDE ANTI-HIV AGENT
Description and properties
A new antiviral agent applicable in HIV-1 therapy has been developed in N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry in collaboration with the Institute of Chemical-Energy Technologies of Siberian Branch of RAS, Institute of Petrochemistry and Catalysis of RAS and Vektor StateScientific Center of Virology and Biotechnology. The compound is synthesized from natural triterpene betuline – available metabolite of birch bark. Anti-HIV activity of the agent is substantially higher than that of azidothimidine.
Technical-Economic Advantages
- Low-toxic inhibitor of embedding the virus into the cell
- Technologically simple. Obtained on the basis of available plant material, which provides at least fivefold decrease in the cost of the annual therapy
Application
- Anti-HIV agent
- Immunostimulant
- Antiherpetic
Patents
Patent of RF № 2211843 of 25.01.2002. “N`-{N-[3-oxo-20(29)-lupene-28-oyl]-9-aminononanoyl}-3-amino-3-phenylpropionic acid with immunopotentiating and antiviral activity.
Practical realization
- The main part of pre-clinical testing is completed
- Pilot plant schedule is developed
N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry,
Siberian Branch of the Russian Academy of Sciences
9, Acad. Lavrentiev Ave, 630090, Novosibirsk, 90, Russsia
PhD< E.E. Shults , Head of the Laboratory
Tel.: (383) 330-85-33 E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.